Gd2O3 nanoparticles in hematopoietic cells for MRI contrast enhancement

As the utility of magnetic resonance imaging (MRI) broadens, the importance of having specific and efficient contrast agents increases and in recent time there has been a huge development in the fields of molecular imaging and intracellular markers. Previous studies have shown that gadolinium oxide (Gd2O3) nanoparticles generate higher relaxivity than currently available Gd chelates: In addition, the Gd2O3 nanoparticles have promising properties for MRI cell tracking. The aim of the present work was to study cell labeling with Gd2O3 nanoparticles in hematopoietic cells and to improve techniques for monitoring hematopoietic stem cell migration by MRI. Particle uptake was studied in two cell lines: the hematopoietic progenitor cell line Ba/F3 and the monocytic cell line THP-1. Cells were incubated with Gd2O3 nanoparticles and it was investigated whether the transfection agent protamine sulfate increased the particle uptake. Treated cells were examined by electron microscopy and MRI, and analyzed for particle content by inductively coupled plasma sector field mass spectrometry. Results showed that particles were intracellular, however, sparsely in Ba/F3. The relaxation times were shortened with increasing particle concentration. Relaxivities, r1 and r2 at 1.5 T and 21°C, for Gd2O3 nanoparticles in different cell samples were 3.6–5.3 s−1 mM−1 and 9.6–17.2 s−1 mM−1, respectively. Protamine sulfate treatment increased the uptake in both Ba/F3 cells and THP-1 cells. However, the increased uptake did not increase the relaxation rate for THP-1 as for Ba/F3, probably due to aggregation and/or saturation effects. Viability of treated cells was not significantly decreased and thus, it was concluded that the use of Gd2O3 nanoparticles is suitable for this type of cell labeling by means of detecting and monitoring hematopoietic cells. In conclusion, Gd2O3 nanoparticles are a promising material to achieve positive intracellular MRI contrast; however, further particle development needs to be performed.

[1]  K. Uvdal,et al.  Positive MRI contrast enhancement in THP-1 cells with Gd2O3 nanoparticles. , 2008, Contrast Media & Molecular Imaging.

[2]  S. Aime,et al.  Biodistribution of gadolinium‐based contrast agents, including gadolinium deposition , 2009, Journal of magnetic resonance imaging : JMRI.

[3]  T. Leiner,et al.  Risk factors for NSF: A literature review , 2009, Journal of magnetic resonance imaging : JMRI.

[4]  U Himmelreich,et al.  Efficient stem cell labeling for MRI studies. , 2008, Contrast media & molecular imaging.

[5]  Kajsa Uvdal,et al.  Synthesis and characterization of PEGylated Gd2O3 nanoparticles for MRI contrast enhancement. , 2010, Langmuir : the ACS journal of surfaces and colloids.

[6]  Dustin J. Maxwell,et al.  Fluorophore‐Conjugated Iron Oxide Nanoparticle Labeling and Analysis of Engrafting Human Hematopoietic Stem Cells , 2008, Stem cells.

[7]  H. Soltanian-Zadeh,et al.  Effects of Ferumoxides – Protamine Sulfate Labeling on Immunomodulatory Characteristics of Macrophage-like THP-1 Cells , 2008, PloS one.

[8]  Ko Kang Ning,et al.  SYNTHESIS AND CHARACTERIZATION OF , 2011 .

[9]  R. Lenkinski,et al.  Nephrogenic systemic fibrosis: a chemical perspective. , 2008, Radiology.

[10]  Hamid Soltanian-Zadeh,et al.  Quantification of superparamagnetic iron oxide (SPIO)‐labeled cells using MRI , 2007, Journal of magnetic resonance imaging : JMRI.

[11]  K. Uvdal,et al.  High proton relaxivity for gadolinium oxide nanoparticles , 2006, Magnetic Resonance Materials in Physics, Biology and Medicine.

[12]  Teodor Veres,et al.  Polyethylene glycol-covered ultra-small Gd2O3 nanoparticles for positive contrast at 1.5 T magnetic resonance clinical scanning , 2007 .

[13]  Marc-André Fortin,et al.  Ultra-small gadolinium oxide nanoparticles to image brain cancer cells in vivo with MRI. , 2010, Contrast media & molecular imaging.

[14]  A. Pałasz,et al.  Toxicological and cytophysiological aspects of lanthanides action. , 2000, Acta biochimica Polonica.

[15]  R Weissleder,et al.  Magnetically labeled cells can be detected by MR imaging , 1997, Journal of magnetic resonance imaging : JMRI.

[16]  V. Pierre,et al.  Next generation, high relaxivity gadolinium MRI agents. , 2005, Bioconjugate chemistry.

[17]  Alain Brenier,et al.  Synthesis and luminescent properties of sub-5-nm lanthanide oxides nanoparticles , 2003 .

[18]  M. Steinmetz,et al.  Interleukin-3 supports growth of mouse pre-B-cell clones in vitro , 1984, Nature.

[19]  Shigeru Tsuchiya,et al.  Establishment and characterization of a human acute monocytic leukemia cell line (THP‐1) , 1980, International journal of cancer.

[20]  Diego R Martin,et al.  Risk of nephrogenic systemic fibrosis: evaluation of gadolinium chelate contrast agents at four American universities. , 2008, Radiology.

[21]  Y. Gossuin,et al.  Impact of agglomeration on the relaxometric properties of paramagnetic ultra-small gadolinium oxide nanoparticles , 2011, Nanotechnology.

[22]  David Vance,et al.  The design of polyvalent scaffolds for targeted delivery. , 2009, Advanced drug delivery reviews.

[23]  J. Bacri,et al.  Interaction of Anionic Superparamagnetic Nanoparticles with Cells: Kinetic Analyses of Membrane Adsorption and Subsequent Internalization , 2002 .

[24]  J. Nolta,et al.  Recent advances in hematopoietic stem cell biology , 2004, Current opinion in hematology.

[25]  W. Heindel,et al.  Cell tagging with clinically approved iron oxides: feasibility and effect of lipofection, particle size, and surface coating on labeling efficiency. , 2005, Radiology.

[26]  P. Perriat,et al.  Hybrid gadolinium oxide nanoparticles: multimodal contrast agents for in vivo imaging. , 2007, Journal of the American Chemical Society.

[27]  Ulrich Heinzmann,et al.  Targeting of hematopoietic progenitor cells with MR contrast agents. , 2003, Radiology.